Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Tetra Bio Pharma Inc TBPMQ

Tetra Bio-Pharma Inc. is a Canada-based cannabinoid-derived drug discovery and development company. The Company has developed a pipeline of cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology. The Company has a pipeline of formulations and drug delivery systems with a portfolio of assets from the early research and development phase to advanced stage clinical programs. Its products include QIXLEEF, CAUMZ, PPP004, REDUVO, and REBORN 1. QIXLEEF is a botanical therapy with a fixed dosage of tetrahydrocannabinol (THC) and cannabidiol (CBD). CAUMZ is its inhaled cannabinoid-derived drug candidate. PPP004 is a topical preparation containing either a standardized amount of CBD or a defined ratio of THC and CBD. REDUVO is a soft gel capsule used to treat chemotherapy-induced nausea and vomiting (CINV) and weight loss and severe nausea in people living with human immunodeficiency virus (HIV) infection. REBORN 1 is in phase II trial.


GREY:TBPMQ - Post by User

Post by SamV21on Feb 07, 2022 1:59pm
100 Views
Post# 34405624

Once again Tetra left in the dust on shareholders $$$

Once again Tetra left in the dust on shareholders $$$
  • VBI-S is an intravenously injectable fluid currently under Phase II clinical evaluation for hypovolemia treatment due to sepsis/septic shock. 
  • CYT107 is a biological product naturally made by the body that may stimulate the immune system to destroy tumour cells. The drug is in phase II of clinical trials for the treatment of sepsis.
  • SY 005 is a dianexin based therapeutics being developed by Lawson Health Research Institute and Yabao Pharmaceuticals to treat Sepsis. In April 2019, Suzhou initiated phase I, a clinical study to evaluate the safety, tolerance and pharmacokinetics of SY-005.
  • HY 209 is a gel formulation of taurodeoxycholic acid, a G protein-coupled receptor 19 (GPCR19) agonist for sepsis treatment. The drug is currently under phase I of clinical trials for the treatment of sepsis.
<< Previous
Bullboard Posts
Next >>